North East and North Cumbria
ICS Formulary
ICS Formulary
4 Central nervous system
04-06 5HT3 antagonists
| Ondansetron |
|
First Choice
|
|
 MHRA Drug Safety Update (Jan 2020): Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy |
|
| Palonosetron |
|
Formulary
|
|
|
| Netupitant & Palonosetron Akynzeo® |
|
Formulary
|
|
|
|
Links
- Metoclopramide: risk of neurological adverse effects
- MHRA Drug Safety Alert (Feb 2015): Drugs and driving: blood concentration limits set for certain drugs
- MHRA Drug Safety Alert (Jul 2013): Ondansetron for intravenous use: dose-dependent QT interval prolongation
- MHRA Drug Safety Alert (May 2014): Domperidone: risk of cardiac side effect
- MHRA Drug Safety Update (Dec 2019): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- MHRA Drug Safety Update (Jan 2020): Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- MHRA Drug Safety Update (Jan 2020): Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- MHRA Drug Safety Update (July 2023): Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia
NENC Palliative and End of Life Care Symptom Control Guidelines- NICE CG84: Vomiting and diarrhoea in children under 5
- NICE NG155: Tinnitus: assessment and management
- NICE NG62: Cerebral palsy in under 25s: assessment and management
- NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
- NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
- TEWV - Medicines Optimisation – Interactive Guide
- TEWV Guidelines
- TEWV Safe Transfer of Prescribing Guidance